Search research articles
Contact Us
Filters
Showing results (51-60 of 129) with videos related to
Page
of 13
Sort By:
Virchows Archiv : an International Journal of Pathology
|
August 3, 2013
Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma
Fumiyoshi Fushimi, Kenichi Taguchi, Hiroto Izumi, et al.
Gynecologic Oncology
|
February 4, 2014
Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer
Shin Nishio, Kimio Ushijima, Tomohiko Yamaguchi, et al.
Cancer Research
|
November 21, 2013
Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma
Hiroyuki Okazaki, Naoya Matsunaga, Takashi Fujioka, et al.
Cancer Science
|
April 27, 2007
Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression
Yoshinao Oda, Yoshihiro Ohishi, Yuji Basaki, et al.
Molecular Cancer Therapeutics
|
March 1, 2013
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells
Tomohiro Shibata, Hitoshi Kan, Yuichi Murakami, et al.
Biochemical and Biophysical Research Communications
|
October 28, 2008
Role of macrophages in inflammatory lymphangiogenesis: Enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation
Kosuke Watari, Shintaro Nakao, Abbas Fotovati, et al.
Oncotarget
|
June 23, 2016
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
Kosuke Watari, Ayumi Nishitani, Tomohiro Shibata, et al.
Biological & Pharmaceutical Bulletin
|
January 11, 2013
Studies on lymphangiogenesis inhibitors from Korean and Japanese crude drugs
Dami Jeong, Kousuke Watari, Takayuki Shirouzu, et al.
Cancer Research
|
October 21, 2010
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
Chizuko Yamamoto, Yuji Basaki, Akihiko Kawahara, et al.
Anticancer Research
|
November 3, 2004
VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo
Yasuji Ueda, Takehiro Yamagishi, Hisao Ikeya, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 129) with videos related to
Sort By:
Page
of 13
Virchows Archiv : an International Journal of Pathology
|
August 3, 2013
Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma
Fumiyoshi Fushimi, Kenichi Taguchi, Hiroto Izumi, et al.
Gynecologic Oncology
|
February 4, 2014
Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer
Shin Nishio, Kimio Ushijima, Tomohiko Yamaguchi, et al.
Cancer Research
|
November 21, 2013
Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma
Hiroyuki Okazaki, Naoya Matsunaga, Takashi Fujioka, et al.
Cancer Science
|
April 27, 2007
Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression
Yoshinao Oda, Yoshihiro Ohishi, Yuji Basaki, et al.
Molecular Cancer Therapeutics
|
March 1, 2013
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells
Tomohiro Shibata, Hitoshi Kan, Yuichi Murakami, et al.
Biochemical and Biophysical Research Communications
|
October 28, 2008
Role of macrophages in inflammatory lymphangiogenesis: Enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation
Kosuke Watari, Shintaro Nakao, Abbas Fotovati, et al.
Oncotarget
|
June 23, 2016
Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma
Kosuke Watari, Ayumi Nishitani, Tomohiro Shibata, et al.
Biological & Pharmaceutical Bulletin
|
January 11, 2013
Studies on lymphangiogenesis inhibitors from Korean and Japanese crude drugs
Dami Jeong, Kousuke Watari, Takayuki Shirouzu, et al.
Cancer Research
|
October 21, 2010
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
Chizuko Yamamoto, Yuji Basaki, Akihiko Kawahara, et al.
Anticancer Research
|
November 3, 2004
VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo
Yasuji Ueda, Takehiro Yamagishi, Hisao Ikeya, et al.
Page
of 13